Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours

Inclusion Criteria:

1. Signed informed consent form must be obtained prior to any research procedure.

2. Histologically or cytologically confirmed diagnosis of metastatic solid tumours

3. ECOG performance status of 0-3;

4. Adequate organ function defined as: ANC≥1.0×10^9/L, PLT≥75×10^9/L, ALB≥25g/L,TBIL≤1.5×ULN, AST≤2.5×ULN, ALT≤2.5×ULN, ALP≤2.5×ULN, Cr≤1.5×ULN;

5. The patient's own PBMCs or PBMCs from a biological parent or child who is willing todonate blood will be used to prepare CAR-NK cells. The parent or child should be ≥18and ≤60 years old, and he or she is able to sign the informed consent for blooddonation by himself/herself;

6. Patients who won't benefit from surgery, or refuse surgical treatment; patients whowon't benefit from chemotherapy, can't tolerate chemotherapy or refuse chemotherapy.

7. Patients volunteer to participate in this study and sign the informed consent form forsubjects;

8. Blood donors sign the informed consent form for blood donors.

9. Blood donors have negative test results for HIV, HBV and HCV;

10. If a subject or blood donor is a female of childbearing potential, she must have anegative urine pregnancy test result.

Exclusion Criteria:

1. Patients who are suffering from uncontrollable or active infectious diseases of thehematological system, cardiovascular system, respiratory system, digestive system,urinary system, or the endocrine system;

2. Patients with immunologic deficiency or autoimmune diseases;

3. Patients with severe hypersensitivity reactions;

4. Patients received other forms of cellular therapies within the last 3 months;

5. Patients received systemic steroids within the last 3 months;

6. Patients who are breastfeeding or pregnant;

7. Patients with brain metastases;

8. Patients who have received an organ transplant.